![]()
- New insights into biological processes involved in cognitive recovery anticipated to lay the scientific foundation for more personalized noninvasive, biomarker-guided biophysics treatments
- First-ever bench-to-bedside study of Fareon Restore™ connects preclinical mechanisms, clinical outcomes and molecular changes associated with approach
SAN FRANCISCO, Nov. 16, 2026 (GLOBE NEWSWIRE) — Fareon, a clinical-stage biophysics company pioneering novel therapies for neurological diseases and psychiatric and neurodevelopmental disorders, today announced its bench-to-bedside research will be presented at Neuroscience 2026, the annual meeting of the Society for Neuroscience (SfN) in Washington, D.C.
The presentation is the first analysis spanning preclinical studies, a randomized, sham-controlled human trial and advanced proteomic analyses linking Fareon’s Microtesla Magnetic Therapy (MMT) biophysics platform, Fareon Restore™, to improvements in cognitive function and molecular changes associated with reduced inflammation and tissue repair.
“We believe the future of treating neurological disease lies in addressing the underlying biology of the brain, not simply managing symptoms,” said Blake Gurfein, PhD, Founder and CEO of Fareon. “What makes this research particularly exciting is that we are beginning to connect the dots between how our technology influences cellular function, the cognitive improvements observed in patients, and the molecular signatures that may help us predict who will benefit from this treatment. This convergence of neuroscience, biophysics, and precision medicine has the potential to fundamentally change how we treat disorders of the brain.”
The clinical findings demonstrate improvements in measures of cognition and emotional well-being among patients with Long COVID-associated cognitive impairment. The findings provide evidence that brief exposures to low-amplitude radiofrequency electromagnetic fields may influence biological processes involved in inflammation, cellular injury and tissue repair. The research also identifies candidate protein biomarkers that could help predict and monitor treatment response, potentially advancing a more personalized approach to treating cognitive impairment.
“Years after the pandemic began, cognitive impairment remains among the most debilitating consequences of Long COVID, preventing many patients from working, caring for their families and participating fully in everyday life, yet no widely established, approved treatment has proven to restore cognitive function or offer meaningful relief,” said David Putrino, Ph.D., Nash Family Director of the Cohen Center for Recovery from Complex Chronic Illness at the Icahn School of Medicine at Mount Sinai and Study Investigator. “These data and the ability to investigate treatment-associated changes and potential predictors of response – are informing the design of larger clinical studies of noninvasive biophysics treatments that offer hope to patients who have waited years for effective Long COVID therapies – as well as those impacted by other neurological and psychological challenges associated with neuroinflammation, oxidative stress and impaired cellular repair.”
Fareon Restore delivers brief exposures to low-amplitude radiofrequency electromagnetic fields called MMT to influence biological processes implicated in neurological dysfunction, without drugs, surgery or invasive procedures. In clinical trials, the treatment was self-administered at home with virtual supervision.
About Our Bench-to-Bedside Research
In laboratory studies, a single brief session of MMT reduced inflammatory signals from immune cells and suppressed toxic oxidative stress in neurons. In an animal model of severe brain inflammation, repeated MMT exposures reduced inflammation and tissue damage. These findings guided the development of Fareon Restore, a biophysics platform that delivers low-intensity magnetic fields to the brain through a lightweight headset.
Fareon Restore has now been evaluated in a pilot study of adults with Long COVID whose cognitive difficulties were confirmed through clinical testing before treatment and tracked with follow-up testing. These difficulties can include trouble remembering information, staying focused, or switching between tasks. Participants were randomly assigned to receive either active or sham (placebo) treatment at home for four weeks. The study team monitored treatment sessions by video and collected blood samples before treatment began and at the end of treatment. Participants then completed follow-up cognitive testing four weeks after treatment ended.
The pilot study found MMT to be safe and well tolerated. In exploratory analyses from this pilot study, participants who received active treatment showed greater improvements on selected tests of memory and thinking speed, and reported greater gains in emotional well-being, compared with those who received sham or placebo.
Blood samples showed changes in proteins involved in inflammation and tissue repair among participants who improved after active treatment. Levels of a different set of proteins, measured before treatment began, were linked to improvements on neurocognitive tests at week eight.
These findings, presented on Monday, November 16, 2026, are shaping plans for larger studies to confirm the clinical results and determine whether measuring these proteins in blood samples can help track MMT treatment response or identify who is most likely to benefit.
Presentation Details
- Abstract title: Transcranial microtesla magnetic fields: preclinical evidence, exploratory clinical signals, and human plasma response signatures in cognitive impairment
- Presenting author: Nathan Brady, PhD
- Date and time: Monday, November 16, 2026, 8:00 a.m.–noon ET
- Poster board: A9
- Location: Walter E. Washington Convention Center, Halls A–C
- Session: LBP019 — D.01. Neurotoxicity, Inflammation, and Neuroprotection
About Fareon
Fareon is pioneering a new class of biophysics therapies designed to noninvasively treat brain disorders through precisely calibrated electromagnetic fields. The company’s Fareon Restore platform delivers proprietary Microtesla Magnetic Therapy (MMT) in order to activate biological pathways associated with resolution of inflammation and oxidative stress, repair, and recovery in the brain. In clinical trials, MMT has been delivered through a lightweight Fareon Restore headset connected to a tabletop console.
Working alongside leading academic and clinical collaborators, Fareon combines biophysics, high-content imaging and AI to systematically map how physical fields influence biology, accelerating the discovery of therapeutic signals and their translation from cellular models to patients. A public benefit corporation, Fareon is developing therapies for clinical populations where existing treatment options remain limited. The company’s lead product is intended to be administered comfortably in an outpatient or home setting and has been well tolerated in clinical studies to date. Learn more at fareon.co.
Media Contact
Shira Derasmo
M: 917-280-2497
shira@cuttlefishpr.com

Media gallery
